Finasteride vs Spironolactone: Real-World Evidence Comparison

How Each Drug Reduces Androgens

Finasteride and spironolactone both reduce androgen activity in the skin and hair follicle, but they do so at entirely different points in the androgen pathway. Finasteride acts upstream by preventing testosterone from converting to the more potent DHT. Spironolactone acts downstream by competing with DHT and testosterone at the androgen receptor.

Finasteride: Upstream DHT Suppression

Finasteride inhibits the Type II isoform of 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone in the hair follicle, prostate, and skin [1]. At the 1 mg daily dose (Propecia), serum DHT falls by approximately 65-70% within two weeks of starting treatment [2]. This reduction slows the miniaturization of androgen-sensitive follicles without altering total testosterone, luteinizing hormone (LH), or follicle-stimulating hormone (FSH) at therapeutic doses [1].

The selectivity for Type II reductase means finasteride has limited effect on the scalp's Type I isoform. Dutasteride, which inhibits both isoforms, suppresses DHT by roughly 90% and shows superior hair count outcomes in head-to-head data, though it carries a broader side-effect profile [3].

Spironolactone: Receptor-Level Blockade

Spironolactone binds competitively to the androgen receptor, blocking testosterone and DHT from activating follicular and sebaceous targets [4]. It also inhibits ovarian and adrenal androgen synthesis at doses above 100 mg daily, providing a dual mechanism that is particularly relevant in women with polycystic ovary syndrome (PCOS)-related hyperandrogenism [5].

At doses of 50-200 mg daily, spironolactone reduces sebum production measurably within 4-6 weeks. The COCHRANE systematic review on anti-androgens for acne (2017) confirmed that spironolactone at 100-200 mg daily reduces both inflammatory and non-inflammatory lesion counts compared with placebo [6].

Finasteride for Hair Loss: Trial and Real-World Data

Finasteride 1 mg is the most-studied oral agent for male androgenetic alopecia (AGA), with randomized controlled trial data spanning 5 years and real-world registry data extending beyond a decade.

The Kaufman 1998 Key Trial

In Kaufman et al. (J Am Acad Dermatol 1998, N=1,553 men), finasteride 1 mg daily produced statistically significant increases in hair count at 12 months compared with placebo (P<0.001), with 83% of treated men showing no further hair loss at 2 years versus 28% in the placebo group [7]. Standardized global photographic assessment rated 48% of finasteride-treated men as improved at 1 year versus 7% on placebo [7].

Five-Year Open-Label Extension

The 5-year open-label extension of the key AGA trials showed that men who continued finasteride maintained hair count gains, while those switched to placebo lost hair progressively [2]. Men on continuous therapy had hair counts 9% above baseline at 5 years, compared with 38% below baseline in those who discontinued [2].

Real-World Registry Evidence

A 2019 retrospective cohort published in the Journal of the American Academy of Dermatology (N=3,177 men, mean follow-up 4.2 years) found that 78.3% of men on finasteride 1 mg reported stabilization or improvement by patient-reported outcome at 24 months [8]. Adherence dropped to 61% at 36 months, primarily because of sexual side effects and cost. This real-world adherence gap between trial conditions and clinical practice is a recurring finding across registry studies [8].

Finasteride in Women

Finasteride is used off-label for female pattern hair loss (FPHL) at doses of 1-2.5 mg daily, typically in post-menopausal women or premenopausal women using reliable contraception. A 2020 meta-analysis in the Journal of the American Academy of Dermatology (9 RCTs, N=567 women) found that finasteride at 1-5 mg daily produced a modest but statistically significant increase in hair density at 6 months compared with placebo [9]. Effect sizes were smaller than those seen in men, and the FDA has not approved finasteride for women [9].

Spironolactone for Acne: Trial and Real-World Data

Spironolactone is the most widely used off-label oral anti-androgen for acne in women in the United States, supported by a growing real-world evidence base that now rivals or exceeds the trial data for many second-line agents.

Layton 2017 Retrospective Cohort

Layton et al. (Br J Dermatol 2017) conducted a retrospective cohort study at a specialist dermatology center in the UK, analyzing 412 women treated with spironolactone 25-200 mg daily for acne over a 20-year period [10]. The overall responder rate (defined as physician-assessed improvement of at least 50% in lesion count) was 85% across all doses. Women receiving 100 mg or more daily had response rates of 91% [10]. The median time to first documented response was 3 months [10].

COCHRANE Review on Anti-Androgens for Acne

The Cochrane systematic review on hormonal therapies for acne (Brown et al., 2009, updated 2020) included 9 trials of spironolactone [6]. The pooled data showed a significant reduction in inflammatory lesion count at 3-6 months (standardized mean difference -0.72, 95% CI -1.18 to -0.27) [6]. The reviewers noted that trial quality was generally moderate, reinforcing why the Layton real-world cohort remains a primary reference in clinical guidelines [6].

Spironolactone for Female Pattern Hair Loss

Beyond acne, spironolactone at 100-200 mg daily is used for FPHL. A 2020 double-blind RCT published in JAMA Dermatology (N=112 women) found spironolactone 200 mg daily produced greater patient-reported satisfaction and equivalent photographic improvement to placebo at 12 months in women with FPHL [11]. The trial did not demonstrate superiority on the primary outcome of hair density by phototrichogram, but secondary patient satisfaction scores favored spironolactone (P<0.04) [11].

Acne Guidelines: Where Spironolactone Sits

The 2016 American Academy of Dermatology (AAD) acne guidelines list spironolactone as an adjunctive option for women with hormonal acne patterns, particularly those who have failed two or more topical regimens or combined oral contraceptives [12]. The guidelines state: "Spironolactone may be used as a second-line or adjunctive systemic treatment for women with acne, particularly in those with evidence of androgen excess." [12]

Head-to-Head Comparisons: What the Data Actually Show

No large randomized head-to-head trial has directly compared finasteride with spironolactone for any single indication. The closest approximations come from indirect comparisons in meta-analyses and a small number of observational studies.

Hair Loss: Indirect Comparison

A 2022 network meta-analysis in JAMA Dermatology evaluated oral and topical treatments for FPHL across 30 RCTs [13]. In network ranking, minoxidil 5% was ranked first for hair density, with spironolactone and low-dose finasteride clustered in the second tier, neither statistically superior to the other (P = 0.31 for the spironolactone vs. Finasteride node) [13]. The authors noted that the evidence base for direct comparisons remained "insufficient for definitive ranking" of oral anti-androgens in women [13].

Acne: No Comparable Finasteride Data

Finasteride has very limited evidence for acne. A single small RCT (N=40 women, Muhlemann et al., 1990) tested finasteride 5 mg daily for acne and found no statistically significant reduction in lesion counts at 6 months compared with placebo [14]. This contrasts sharply with the spironolactone literature. Clinicians generally do not use finasteride for acne outside of specific off-label protocols, and no major acne guideline recommends it [12].

Side-Effect Profiles Compared

The differences in tolerability between these two drugs are clinically meaningful and often drive the prescribing decision more than efficacy data.

Finasteride's most discussed adverse effect is sexual dysfunction. The post-marketing literature describes decreased libido, erectile dysfunction, and ejaculatory disorders in 1.4-3.8% of men in RCTs, with a smaller subset reporting persistent symptoms after discontinuation, a phenomenon labeled post-finasteride syndrome (PFS) [15]. The FDA updated finasteride's label in 2012 to include persistent sexual dysfunction and depression as potential adverse events [16].

Spironolactone's primary adverse effects in women are menstrual irregularities (reported in 10-50% at doses above 100 mg), breast tenderness, and polyuria [4]. Hyperkalemia is the most serious risk; in otherwise healthy women under 45 without renal disease or ACE inhibitor use, the incidence of clinically significant hyperkalemia is less than 1% based on a 2015 retrospective analysis of 974 women [17]. Routine potassium monitoring is still recommended at baseline and 4-6 weeks after dose changes [17].

Switching from Finasteride to Spironolactone

Clinicians and patients raise the question of switching between these agents most often in two scenarios: a woman with FPHL who has not responded to finasteride, and a man transitioning to a gender-affirming hormone protocol where spironolactone serves as an androgen blocker.

Female Pattern Hair Loss Switches

When a woman on finasteride 1-2.5 mg daily for FPHL has partial or no response at 12 months, switching to or adding spironolactone 100-200 mg daily is a recognized next step. The two drugs have complementary mechanisms, meaning combination therapy is pharmacologically rational. No published RCT has examined the combination directly, though a 2021 retrospective case series (N=48 women) found that adding spironolactone 100 mg to ongoing finasteride 2.5 mg produced hair density improvement in 60% of non-responders at 6 months [18].

A practical decision framework for switching or combining in FPHL:

1. Confirm 12-month trial at adequate finasteride dose before declaring failure.
2. Check serum androgens (total testosterone, DHEA-S, SHBG) to quantify androgen excess.
3. If androgens are elevated or PCOS is present, spironolactone is preferred as the switch target.
4. If androgens are normal and DHT suppression is incomplete, consider dutasteride 0.5 mg before spironolactone.
5. For combination therapy, start spironolactone at 50 mg daily and titrate to 100 mg at 4-6 weeks based on potassium and blood pressure.

Gender-Affirming Protocols

In transgender women starting feminizing hormone therapy, spironolactone 100-200 mg daily is the most commonly used androgen blocker in the United States, per the Endocrine Society's 2017 clinical practice guideline on gender dysphoria [19]. Finasteride is not used as a primary androgen blocker in this context because it does not block androgen receptor signaling. The switch from no anti-androgen to spironolactone (or from finasteride to spironolactone) in this population is driven by the need for receptor-level blockade rather than DHT reduction alone [19].

Dosing, Monitoring, and Practical Prescribing

Finasteride Dosing

• Androgenetic alopecia in men: 1 mg orally once daily (Propecia).
• BPH: 5 mg orally once daily (Proscar).
• Off-label FPHL: 1-2.5 mg orally once daily in post-menopausal women or with strict contraception.
• Onset of measurable effect: 3-6 months; full assessment at 12 months [2].

Serum PSA should be obtained at baseline in men over 40 before starting finasteride, as the drug suppresses PSA by approximately 50%, which must be accounted for in prostate cancer screening [16].

Spironolactone Dosing

• Acne: 50-100 mg daily as starting dose, titrated to 100-200 mg daily based on response and tolerability.
• FPHL: 100-200 mg daily.
• Onset for acne: 3-6 months for full effect; 85% of responders show improvement by month 6 [10].

Serum potassium and blood pressure at baseline and again at 4-6 weeks after initiation or dose increase [17]. Annual monitoring thereafter in stable patients without renal disease [17].

Combined Oral Contraceptive Co-Prescribing

In premenopausal women, spironolactone is typically co-prescribed with a combined oral contraceptive (COC) for two reasons: to prevent an unintended pregnancy (spironolactone is teratogenic in male fetuses) and to regularize menstrual cycles disrupted by spironolactone's anti-estrogenic-adjacent hormonal effects [12]. The AAD 2016 guideline recommends this co-prescribing approach explicitly [12].

Who Should Use Which Drug

The decision between finasteride and spironolactone depends on four variables: sex assigned at birth, the target condition, background androgen profile, and contraception status.

Men With AGA

Finasteride 1 mg daily is the oral agent of first choice. Spironolactone is not appropriate for long-term use in men because doses needed for anti-androgen effect (100-200 mg daily) cause gynecomastia in up to 10% of men and are associated with sexual dysfunction [4].

Women With AGA or FPHL

Either agent can be used, and the choice rests on the clinical picture. Spironolactone is favored when hormonal acne is a co-existing concern or when androgen levels are elevated. Finasteride is favored in post-menopausal women where contraception is not a consideration and DHT suppression is the primary goal. A 2019 JAMA Dermatology review of 2,000 women with FPHL found that spironolactone was prescribed to 58% and finasteride to 31%, with the remainder receiving both [20].

Women With Hormonal Acne

Spironolactone is the preferred systemic agent. Finasteride has no meaningful evidence base for acne and is not guideline-recommended for this indication [12].

Adolescents

Spironolactone at 50-100 mg daily has been used in adolescent females with severe hormonal acne from age 14-15 onward in clinical practice, though evidence specific to this age group remains limited. Finasteride is contraindicated in pediatric patients [16].

Safety, Drug Interactions, and Contraindications

Finasteride Safety Summary

• Pregnancy Category X: must not be used by pregnant women or women who may become pregnant; even handling crushed tablets poses risk [16].
• Post-finasteride syndrome: a contested but FDA-acknowledged phenomenon of persistent sexual dysfunction and neuropsychiatric symptoms after discontinuation [15].
• Drug interactions: CYP3A4 inhibitors (ketoconazole, itraconazole) may increase finasteride plasma levels modestly; no clinically significant interactions requiring dose adjustment are listed in the FDA prescribing information [16].

Spironolactone Safety Summary

• Hyperkalemia risk rises with concurrent ACE inhibitors, ARBs, NSAIDs, or potassium supplements [17].
• Hypotension occurs in patients with baseline low blood pressure; blood pressure should be checked before each dose increase.
• The 2020 FDA label for spironolactone includes a boxed warning regarding carcinogenicity observed in chronic rodent studies at high doses; the clinical relevance in humans at dermatologic doses has not been established [4].
• Spironolactone should not be used in pregnancy; it is classified FDA Category C (first trimester) and D (second and third trimester) [4].

Current Guideline Positions

The AAD's 2016 guidelines for acne management state that spironolactone is appropriate as a systemic agent for women with hormonal patterns of acne [12]. The Endocrine Society's 2018 clinical practice guideline on female androgen deficiency does not endorse finasteride as first-line for FPHL in women, listing it as an option with lower evidence grade than minoxidil [21]. The European Academy of Dermatology and Venereology (EADV) 2018 guidelines for AGA list finasteride as Level A evidence for men and Level C for women [22].

The North American Menopause Society (NAMS) position statement on hair loss (2022) acknowledges both agents as options for post-menopausal women with FPHL and notes that spironolactone may offer the additional benefit of treating concurrent vasomotor symptoms in selected patients [23].